New funding for new marketing strategy at Calpyte:
This article was originally published in Clinica
Executive Summary
Urine-based diagnostic company Calpyte Biomedical last week completed a $2.7m financing, including $2.1m in new funding by a private investment group. The Alameda, California-based company will spend the money on marketing its two HIV-1 urine antibody tests, which the company believes have not been adequately promoted. Executive chairman, Anthony Cataldo, said: "We therefore intend to embark upon an aggressive marketing and educational programme."